-
Article
The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma
Immune checkpoint receptors (ICR) modulate the immune response and are critical hubs for immunotherapy. However, data on their role in T lymphoid malignancies, such as cutaneous T cell lymphoma (CTCL), is spar...
-
Article
COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma
-
Article
Open AccessLong-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT015...
-
Article
Identification of bacteria-derived HLA-bound peptides in melanoma
A variety of species of bacteria are known to colonize human tumours1–11, proliferate within them and modulate immune function, which ultimately affects the survival of patients with cancer and their responses to...
-
Article
Open AccessImmunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
Predicting the outcome of immunotherapy treatment in melanoma patients is challenging. Alterations in genes involved in antigen presentation and the interferon gamma (IFNγ) pathway play an important role in th...
-
Article
Open AccessPredicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
At present, immune checkpoint inhibitors, such as pembrolizumab, are widely used in the therapy of advanced non-resectable melanoma, as they induce more durable responses than other available treatments. Howev...
-
Article
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses that are induced by the combined inhibition of BRAF and MEK1. Here we performed a randomized phase 2 trial ( ...
-
Article
Neurologic complications of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICPIs) have recently emerged as a novel treatment for cancer. These agents, transforming the field of oncology, are not devoid of toxicity and cause immune-related side effects wh...
-
Article
Melanoma in Pregnancy: Therapeutic Challenges
Cancer-complicating pregnancy is a rare coexistence. The therapeutic management of the pregnant patient with cancer is especially difficult because it involves two persons, the mother and the fetus. Malignant ...
-
Article
Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells
We are exploring cell-based vaccines as a treatment for the 50% of patients with large primary uveal melanomas who develop lethal metastatic disease. MHC II uveal melanoma vaccines are MHC class I+ uveal melanoma...
-
Article
Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin
Introduction Several epidemiologic studies have provided suggestive evidence of a link between coetaneous malignant melanoma (CMM) and breast cancer. The Breast Cancer Linkage Consortium (BCLC) reported approxima...
-
Chapter
Functional Cytotoxicity of T Cells in the Tumor Microenvironment
Cytotoxic T cells (CTLs) take a central part in tumor cell destruction. Initially, naïve CD8+ T cells are primed by antigen presenting cells in lymphoid tissue or, alternatively, by antigen processing tumor ce...
